Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Becoming a Life Sciences Lawyer – The View From Goodwin (Chambers Associate)

Related Content

AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments

Top 10 Issues in Cross-Border Life Sciences Transactions

Enforcement Intensifies as Medicaid Cuts Take Hold

Year in Review: Top Legal Developments of 2025

To Monetize or Not to Monetize? The Question Late-Stage Life Sciences Companies Should Be Asking

2026 HSR Thresholds Announced: $133.9 million

Year in Review: Big Deals of 2025

Life Sciences Capital Markets: Preparing for Your 2026 IPO

The Future of Life Sciences Antitrust

Goodwin Advises Kelun-Biotech in Strategic Partnership with Crescent Biopharma to Develop and Commercialize Novel Oncology Therapeutics

Flow Neuroscience Announces FDA Approval of World’s First At-Home Brain Stimulation Treatment for Depression

Goodwin Advises BridgeBio in $632.5 Million Convertible Senior Notes Offering Due 2033

Goodwin Advises Isomorphic Labs on Strategic AI-Driven Research Collaboration with Johnson & Johnson

Inside Goodwin's Client Immersion Program for Junior Associates with Lynda Galligan and Josh Klatzkin (Big Law Life)

Goodwin Named a Law360 Practice Group of the Year for Life Sciences and Benefits

Trump’s Drug Pricing Proposals Draw Legal Questions From Pharma (Bloomberg Law)

Life Sciences

Intellectual Property